One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.

Varela A, Chouinard L, Lesage E, Smith SY, Hattersley G

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research17 Oct 2016Cited by 55 (Europe PMC)

PMID27748532DOI10.1002/jbmr.3003PepBankPUB-27748532

Publisher page PubMedAsk about this study

Jump to 16 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study16

16 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased biochemical bone formation markers.
In plain wordsIn rats, abaloparatide increased bone formation markers compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBiochemical bone formation markers
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide increased biochemical bone formation markers without increasing bone resorption markers or causing hypercalcemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853201
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide did not increase bone resorption markers.
In plain wordsIn rats, abaloparatide did not increase bone breakdown markers compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeBone resorption markers
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide increased biochemical bone formation markers without increasing bone resorption markers or causing hypercalcemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853202
03AnimalAnimal study (in vivo)Safety outcome
In ovariectomized rats, abaloparatide did not cause hypercalcemia.
In plain wordsIn rats, abaloparatide did not cause high blood calcium compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeHypercalcemia
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Adverse events · Endocrine and hormones
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide increased biochemical bone formation markers without increasing bone resorption markers or causing hypercalcemia.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853203
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased histomorphometric bone formation indices on trabecular surfaces.
In plain wordsIn rats, abaloparatide increased bone formation on trabecular surfaces compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular bone formation
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide increased histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces without increasing osteoclasts or eroded surfaces.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853204
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased histomorphometric bone formation indices on endocortical surfaces.
In plain wordsIn rats, abaloparatide increased bone formation on inner cortical surfaces compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseEndocortical bone formation
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide increased histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces without increasing osteoclasts or eroded surfaces.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853205
06AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased histomorphometric bone formation indices on periosteal surfaces.
In plain wordsIn rats, abaloparatide increased bone formation on outer bone surfaces compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreasePeriosteal bone formation
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide increased histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces without increasing osteoclasts or eroded surfaces.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853206
07AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide did not increase osteoclasts.
In plain wordsIn rats, abaloparatide did not increase bone-resorbing cells compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeOsteoclasts
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide increased histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces without increasing osteoclasts or eroded surfaces.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853207
08AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide did not increase eroded surfaces.
In plain wordsIn rats, abaloparatide did not increase eroded bone surfaces compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
No significant changeEroded surfaces
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide increased histomorphometric indices of bone formation on trabecular, endocortical, and periosteal surfaces without increasing osteoclasts or eroded surfaces.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853208
09AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased trabecular bone volume.
In plain wordsIn rats, abaloparatide increased trabecular bone volume compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular bone volume
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853209
10AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased trabecular bone density.
In plain wordsIn rats, abaloparatide increased trabecular bone density compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular bone density
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853210
11AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide improved trabecular microarchitecture.
In plain wordsIn rats, abaloparatide improved trabecular bone structure compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTrabecular microarchitecture
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide induced substantial increases in trabecular bone volume and density and improvements in trabecular microarchitecture.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853211
12AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide stimulated periosteal expansion at the tibial diaphysis.
In plain wordsIn rats, abaloparatide increased expansion of the outer tibial bone surface compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTibial periosteal expansion
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853212
13AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide stimulated endocortical bone apposition at the tibial diaphysis.
In plain wordsIn rats, abaloparatide increased bone deposition on the inner tibial surface compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTibial endocortical apposition
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853213
14AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased cortical bone volume.
In plain wordsIn rats, abaloparatide increased cortical bone volume compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCortical bone volume
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853214
15AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased cortical bone density.
In plain wordsIn rats, abaloparatide increased cortical bone density compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseCortical bone density
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5, or 25 μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide stimulated periosteal expansion and endocortical bone apposition at the tibial diaphysis, leading to marked increases in cortical bone volume and density.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853215
16AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, whole-body BMD increased with abaloparatide while remaining stable with vehicle.
In plain wordsIn rats, whole-body bone density increased with abaloparatide but remained stable with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseWhole-body BMD
Study
ratn: not reported in source
osteopenic ovariectomized Sprague-Dawley rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
25 μg/kg · subcutaneous · 12 monthsAs given in this study (rat).
Measurements
BMD increase
25%
abaloparatide after 12 months
Source sentences
Summary
Whole-body bone mineral density (BMD) remained stable in OVX-Vehicle controls while increasing 25% after 12 months of abaloparatide (25 μg/kg).
1 context sentence(design, population, supporting numbers)
Summary · context
Ten OVX rats were euthanized after this bone depletion period, and the remaining OVX rats received daily subcutaneous injections of vehicle (n = 18) or abaloparatide at 1, 5, or 25 μg/kg/d (n = 18/dose level) for 12 months.
Report a problemFND-2774853216

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

One Year of Abaloparatide, a Selective Activator of the PTH1 Receptor, Increased Bone Formation and Bone Mass in Osteopenic Ovariectomized Rats Without Increasing Bone Resorption.

Summary

Results from this study16

Version history

Subjects

Publication types

MeSH terms

Keywords